Michael Becka

Serum markers detect the presence of liver fibrosis: A cohort study

William Rosenberg, Michael Voelker, Robert Thiel et al. · Gastroenterology · 2004 · 1.1K citations · Full text

Liver Fibrosis, Fibrosis, Hepatology +13

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

Dagmar Kubitza, Michael Becka, Barbara Voith et al. · Clinical Pharmacology & Therapeutics · 2005 · 652 citations

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

Dagmar Kubitza, Michael Becka, Georg Wensing et al. · European Journal of Clinical Pharmacology · 2005 · 648 citations

Therapeutic Drug Monitoring, Pharmacology, Clinical Pharmacology +5

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

Dagmar Kubitza, Michael Becka, Wolfgang Mueck et al. · British Journal of Clinical Pharmacology · 2010 · 426 citations · Full text

Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

Wolfgang Mueck, Dagmar Kubitza, Michael Becka · British Journal of Clinical Pharmacology · 2013 · 364 citations · Full text